In Oct 2007, the FDA announced which the labeling for all PDE5 inhibitors, like tadalafil, requires a additional outstanding warning from the opportunity danger of unexpected Listening to loss as the results of submit-advertising reviews of momentary deafness associated with use of PDE5 inhibitors.[